Gene
Response to Interferon Therapy for Hepatitis C Differs by Race Several
studies have shown that individuals of African descent respond less well to interferon-based
therapy for chronic hepatitis C, with a significantly lower proportion of
black than white patients achieving sustained
virological response. As
reported in the August 2006 issue of Hepatology, researchers from Stanford
University School of Medicine conducted a study to investigate the underlying
host immune responses associated with interferon treatment outcomes. The authors
collected peripheral blood mononuclear cells from chronic hepatitis C patients
before initiation of interferon therapy; cells were incubated with or without
interferon-alpha for six hours. They then used a microarray assay to identify
whether gene transcription was stimulated by interferon. Results
The global induction of interferon-stimulated genes was significantly greater
in sustained virological responders compared with non-responders.
Interferon-stimulated gene transcription was also greater in white patients compared
with black patients.
Significantly greater global induction of interferon-stimulated genes was observed
in sustained virological responders compared with nonresponders within the group
of white patients.
The level of interferon-induced signal transducer and activator of transcription
(STAT)-1 activation -- a key component of the JAK-STAT interferon-signaling pathway
-- correlated with the global induction of interferon-stimulated genes.
STAT-1 activation was significantly higher in white patients than in black patients.
Conclusion "[B]oth
treatment outcome and race are associated with different transcriptional responses
to interferon-alpha," the authors concluded. "Because this difference
is evident in the global induction of interferon-stimulated genes rather than
a selective effect on a subset of such genes, key factors affecting the outcome
of interferon-alpha therapy are likely to act at the JAK-STAT pathway that controls
transcription of downstream interferon-stimulated genes." 8/21/06 Reference X
S He, X Ji, M B Hale, and others. Global transcriptional response to interferon
is a determinant of HCV treatment outcome and is modified by race. Hepatology
44(2): 352-359. August 2006. |